



Marked-up Copy of Claims as presented in the March 26, 2007 amendment

1. (Currently amended as presented in the March 26 2007 amendment) A method of inhibiting blood supply to a tumor, comprising the steps of:

- (a) locating an artery which carries major blood supply to the tumor, said artery being one that is proximate to the tumor;
and
- (b) intra-arterially injecting into the located artery a predetermined quantity of one or more anti-angiogenic substance(s), [a salt solution mixture of a polyunsaturated fatty acid in the form of a salt solution] and a salt of at least one polyunsaturated fatty acid chosen from linolenic acid, gamma-linolenic acid, dihomogamma-linolenic acid, arachidonic acid, alpha-linolenic acid, eicosapentaenoic acid, docosahexaenoic acid and cis-parinaric acid [and one or more anti-angiogenic substance(s)].

2. (Original) A method as in claim 1 comprising the step of causing antiangiogenic action, wherein said polyunsaturated fatty acid is in the form of a lithium salt solution and wherein said predetermined quantity of the fatty acid is generally in a range of 0.5 mg to 50 gm.

3. (Previously presented) A method as in claim 1 wherein step (b) comprises intra-arterially injecting said predetermined quantity of a polyunsaturated fatty acid in the

form of a lithium salt solution of a polyunsaturated fatty acid, wherein said anti-angiogenic substance is to the extent of 1 to 1000 mg/kg/ body weight, said solution of polyunsaturated fatty acid further comprising a substance chosen from glycerides, esters, free acids, amides, phospholipids and salts.

4. (Original) A method as in claim 1, wherein the polyunsaturated fatty acid is in the form of a lithium salt solution of gamma-linolenic acid and

eicosapentaenoic acid/docosahexaenoic acid, including a predetermined quantity of said anti-angiogenic substance chosen from: an anti-

angiogenic substance naturally occurring as a protein, platelet factor-4,

TNP-470, thalidomide, interleukin-12, and metalloprotease inhibitors,

and a predetermined anti-cancer drug.

5. (Original) A method of treating a tumor and facilitating visualization of remission of the tumor responsive to treatment, comprising :

(a) locating an artery which carries a major portion of blood supply to

said tumor and is adjacent to the tumor;

(b) obtaining an initial radiographic image of the tumor region;

(c) injecting into the located artery a mixture of at least

(i) an oily lymphographic agent as a carrier containing one or more

of anti-angiogenic substance(s)

(ii) a lithium salt solution of at least one polyunsaturated fatty acid

chosen from linolenic acid, gamma-linolenic acid, dihomo-gamma-

linolenic acid, arachidonic acid, alpha-linolenic acid,

eicosapentaenoic acid, docosahexaenoic acid and cis-parinaric

acid

(d) obtaining second and subsequent radiographic images of the tumor

region after predetermined lapses of time; and

(e) comparing the initial radiographic image with the second and

subsequent images to assess an extent of remission of the tumor.

6. (Previously presented) A method as in claim 5 wherein step (c) comprises intra-arterially injecting said mixture containing components chosen from : an anti-

angiogenic substance naturally as a protein, platelet factor-4, TNP-

470, thalidomide, and interleukin-12, causing anti-angiogenic action by

inhibiting the blood supply to the tumor, wherein further the oily

lymphographic agent acts as a carrier for said anti-angiogenic

substance(s), and also for the lithium salt solution of predetermined

quantities of gamma-linolenic acid, eicosapentaenoic acid and/or docosahexaenoic acid.

7. (Previously presented) A method of treating a cancerous tumor, comprising

(a) using an oily lymphographic agent as a carrier for

- (i) at least one polyunsaturated fatty acid chosen from a lithium salt of at least one of linolenic acid, gamma-linolenic acid, dihomo-gamma-linolenic acid, arachidonic acid, alpha-linolenic acid, eicosapentaenoic acid, docosahexaenoic acid, and cis-parinaric acid; and,
- (ii) a predetermined anti-cancer drug, and anti-angiogenic substance(s) mixed with polyunsaturated fatty acids or coupled with fatty acids; and,

(b) administering, by injecting into said cancerous tumor a predetermined quantity of the fatty acids, anti-cancer drug and predetermined anti-angiogenic substance in the oily lymphographic agent as a carrier.